Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 3/20 | 0.50 |
| ▸ | MMP3 | P08254 | 2/20 | 0.50 |
| ▸ | MMP7 | P09237 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324078 | 0.86 | SIGMAR1 (0.51) | ALDH1A1SIGMAR1CA1CA2GBA1 | |
| SCHEMBL3412348 | 0.86 | CA1 (0.52) | ALDH1A1SIGMAR1CA1CA2GBA1 | |
| SCHEMBL3412102 | 0.86 | CA1 (0.52) | ALDH1A1SIGMAR1CA1CA2GBA1 | |
| SCHEMBL6321465 | 0.86 | CA1 (0.52) | ALDH1A1SIGMAR1CA1CA2GBA1 | |
| SCHEMBL7862567 | 0.83 | GBA1 (0.74) | ALDH1A1CA1CA2GBA1GAA | |
| SCHEMBL6597702 | 0.83 | GAA (0.49) | ALDH1A1SIGMAR1CA1CA2GBA1 | |
| SCHEMBL6034629 | 0.83 | SIGMAR1 (0.53) | ALDH1A1SIGMAR1CA1CA2GBA1 | |
| SCHEMBL15771953 | 0.82 | ALDH1A1 (0.73) | ALDH1A1CA1CA2GBA1GAA | |
| SCHEMBL3153289 | 0.82 | SIGMAR1 (0.59) | ALDH1A1SIGMAR1CA1CA2GAA | |
| SCHEMBL27287741 | 0.82 | GRIA4 (0.56) | ALDH1A1SIGMAR1GBA1CYP19A1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668856-B1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| EP-3145912-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382222-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9302985-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9302985-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9302985-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2015177325-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015177325-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| WO-2008109055-A2 | CYANOPYRROLE SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1012142-A1 | 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 | Merck Frosst Canada & Co. (CA) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999014194-A1 | 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA & CO. (CA) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CHAT, GRIN2C, GRIN2A | ALDH1A1 1162/4885SIGMAR1 792/4885CA1 470/4885 |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | OPRK1, OPRD1, OPRL1 | ALDH1A1 259/4885SIGMAR1 27/4885CA1 1362/4885 |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | PKD1, PKD2, SHBG | ALDH1A1 1586/4885SIGMAR1 2903/4885CA1 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.